Bioinvent investor relations
WebJun 16, 2024 · Cecilia Hofvander, Senior Director Investor Relations Phone: +46 (0)46 286 85 50 Email: [email protected] Martin Welschof, CEO +46 (0)46 286 85 50 [email protected] BioInvent International AB (publ) Co. Reg. No. Org nr: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 … WebOct 27, 2024 · Cecilia Hofvander, Senior Director Investor Relations Phone: +46 (0)46 286 85 50 Email: [email protected]. BioInvent International AB (publ) Co. Reg. No. Org nr: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 www.bioinvent.com
Bioinvent investor relations
Did you know?
WebBioInvent: Martin Welschof, CEO +46 (0)46 286 85 50 [email protected] . Cecilia Hofvander, Senior Director Investor Relations +46 (0)46 286 85 50 … WebNov 27, 2024 · LUND, Sweden, Nov. 27, 2024 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and …
WebMar 23, 2024 · LUND, Sweden, March 23, 2024 /PRNewswire/ -- BioInvent International AB's (publ) ("BioInvent") (Nasdaq Stockholm: BINV) Extraordinary General Meeting (the "EGM") today resolved to approve the ... WebJul 29, 2024 · Senior Director Investor Relations ... BioInvent International AB (publ) Co. Reg. No. Org nr: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50
WebCASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2024 ... Cecilia Hofvander, Senior Director Investor Relations +46 (0)46 286 85 50 +46 (0)46 286 85 50 ... 240-864-2643 [email protected] INVESTOR CONTACT: Solebury Trout Xuan Yang 646-378-2975 [email protected]: About Us. WebNov 18, 2024 · BioInvent has four drugs in five clinical trials, underlining productivity of proprietary technology platform ... Cecilia Hofvander, Senior Director Investor Relations Phone: +46 (0)46 286 85 50 ...
WebBioInvent has a strong deal-making track record, and has ongoing collaborations with companies such as CASI, Exelixis, Pfizer, Merck, Daiichi and Mitsubishi Tanabe. Broad …
iplato downloadWebAug 26, 2024 · BioInvent received IND approval for Phase 1/2a trial of anti-TNFR2 antibody BI-1808. ... Cecilia Hofvander, Investor Relations +46 (0)46 286 85 50 [email protected] ... oras ineuWebNov 27, 2024 · LUND, Sweden, Nov. 27, 2024 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced today the appointment of Cecilia Hofvander as Senior Director Investor … iplat crmWebNov 27, 2024 · --BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer … iplato toolbarWebMar 8, 2024 · BI-1808 is an antibody from BioInvent's n-CoDeR/F.I.R.S.T™ platform directed against tumor necrosis factor receptor-2 (TNFR2). The results from the toxicological studies demonstrate a very good ... iplato creditsWebBioinvent. BioInvent International is a Swedish clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer … iplasticWebApr 6, 2024 · Cecilia Hofvander, Senior Director Investor Relations Phone: +46 (0)46 286 85 50 Email: [email protected]. BioInvent International AB (publ) Co. Reg. No. Org nr: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 www.bioinvent.com. iplast holding